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Limitations of EBV–PCR monitoring
to detect EBV associated post-transplant
lymphoproliferative disorder
The development of PTLD continues to be a
major cause of morbidity and mortality among
pediatric patients undergoing solid organ trans-
plant. PTLD affects approximately 2% of solid
organ recipients; however, children are dispro-
portionately affected (1). PTLD is believed to
result from primary infection or re-activation of
EBV among immunosuppressed organ recipients,
leading to a spectrum of diseases including
malignant transformation. PTLD is associated
with a wide spectrum of histopathologies, ran-
ging from early hyperplastic lesions resembling
infectious mononucleosis to true B-cell lympho-
mas (2). In addition, transplant recipients have
developed Hodgkin’s disease, T-cell and null-cell
lymphomas, which are currently considered
within the spectrum of PTLD, although this
remains somewhat controversial (2).
Children with PTLD present with non-specific
symptoms including fever, lethargy or malaise,
diarrhea, and non-specific physical signs inclu-
ding hepatosplenomegaly and diffuse lympha-
denopathy. Clinicians have utilized serologic
markers of EBV infection to assist in the diag-
nosis; however, seroconversion may not occur in
up to 37% of pediatric patients with PTLD (1).
More recently, the use of peripheral blood PCR
monitoring of EBV DNA has been shown to be a
sensitive and specific method of identifying
children at increased risk of developing PTLD
(3). While early reports using RQ–PCR in serum,
suggested that PCR was 100% sensitive and
100% specific for the detection of PTLD in
children with >1000 copies of EBV per 100 lL
plasma, recent studies have suggestive that mon-
itoring is relatively less sensitive but remains
fairly specific (4, 5). Similarly, significantly
elevated viral loads were found in 10 of 10
patients with known PTLD using a TaqMan
based EBV–PCR assay (6).
EBV–PCR in PBLs has been widely applied
clinically in our institution and is used as an
initial diagnostic evaluation in patients with
suspected EBV induced PTLD (7). However, in
this report, we described two patients with
pathologically proven PTLD associated with
EBV who had no sustained elevation in virus
detected using PCR above 100 copies per 105
lymphocytes.
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Abstract: Post-transplant lymphoproliferative disorder (PTLD) repre-
sents a significant threat to the survival of pediatric transplant recipi-
ents. Epstein–Barr (EBV) viral load monitoring using polymerase chain
reaction (PCR) has been reported to have a variable sensitively with
relatively higher specificity as in an indicator of the development of
PTLD. We report two cases of pathologically confirmed PTLD in
children who failed to develop sustained increases in their EBV–PCR
determined viral loads. We suggest that clinicians should be aware of
the potential for false-negative results of EBV–PCR in pediatric trans-
plant recipients.
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Clinical and laboratory records were reviewed for patients
who developed PTLD following solid organ transplanta-
tion. Two children were identified who developed biopsy
proven PTLD, which was EBV positive based on specimen
immunohistochemistry. In each case, viral load was mon-
itored using the quantitative competitive PCR method
described by Rowe and colleagues and is reported as the
number of viral DNA copies per 105 PBLs. A value of >500
copies per 105 PBLs was considered to be suggestive of
PTLD (3). This project was reviewed and approved by
the University of Michigan Medical Center Institutional
Review Board and the parents of both children authorized
publication. The initials presented have been changed to
further protect the anonymity of the children.
Results
Case report 1
AA was the product of a 32 wk twin gestation
who was born at 2.2 kg. Shortly after birth, AA
presented to her primary care physicians with
fussiness and irritability. Laboratory studies
obtained as part of an evaluation for sepsis
revealed a total protein of 2.8 g/dL and an
albumin of 1.0 g/dL. AA was subsequently
diagnosed with congenital nephrotic syndrome.
AA was managed with dietary supplementation
and i.v. albumin until 6 months of age. At this
time, AA underwent bilateral nephrectomy to
prevent ongoing proteinuria. AA was managed
on hemodialysis for 22 days and subsequently
underwent a living related renal transplant from
her mother in 1993 at the University of Michigan
Medical Center. AA was CMV sero-negative and
EBV sero-negative and received a CMV positive
organ. AA received ATGAM induction and her
initial immunosuppression included prednisone,
cyclosporine, and azathioprine. AA did well after
transplant aside from reflux at her ureteroneo-
cystostomy requiring collagen injections and
re-implantation. AA developed a rising creati-
nine 36 months post-transplant. Graft biopsy
was consistent with chronic cyclosporine toxicity
and her immunosuppression was changed from
azathioprine to MMF.
AA’s clinical course remained stable until
90 months after transplantation during this
which time AA was treated with growth hormone
for 30 months for short stature. AA then pre-
sented with fever to 103 F. AA was initially
treated for bronchitis at an outside hospital and
discharged with persistent, intermittent fevers.
AA subsequently presented to the University of
Michigan with fevers to 105 and an elevated
creatinine. No source for her fever was identified.
A renal biopsy revealed chronic cyclosporine
toxicity and evidence of acute tubular necrosis.
Her cyclosporine dosed was reduced. Addition-
ally, serologic studies for CMV were negative.
An EBV–PCR was also obtained, and no virus
was detectable in the patient’s peripheral
lymphocytes (Table 1). AA was re-admitted
8 days later with persistent fever. A CT scan of
her chest, abdomen, and pelvis demonstrated
marked mediastinal and retroperitoneal lympha-
denopathy with mild tracheal compression. Open
lymph node biopsy of a paratracheal node
revealed classic Reed–Sternberg cells and Reed–
Sternberg cell variants in a background rich
in reactive histiocytes and small lymphocytes.
Immunohistochemistry revealed that the malig-
nant cells were EBV–LMP positive. This biopsy
was determined to be consistent with classical
Hodgkin’s disease. Repeat serum PCR obtained
at the time of this biopsy was 20 genomes per 105
lymphocytes.
Following diagnosis, MMF and Cyclosporine
were withdrawn and chemotherapy initiated. AA
was treated with six cycles of COPP/ABV (cyt-
oxan, prednisone, vincristine, procarbazine, vel-
ban, bleomycin, and adriamycin). Four months
after the initiation of therapy, CT scan revealed
no evidence of recurrent disease. Cyclosporine
was restarted 8 months following diagnosis. At
the time of her most recent follow-up, AA is now
8 yr post-transplant and 15 months after her
diagnosis of PTLD. AA is without evidence of
recurrence of her Hodgkin’s lymphoma and her
creatinine is 1.2 mg/dL.
Case Report 2
BB was referred for liver transplant evaluation at
age seven. BB was diagnosed with biliary atresia
in childhood and underwent a Kasai procedure
at 2 months of age. At the time of his transplant
evaluation, BB had experienced several episodes
of gastrointestinal bleeding as a result of his
significant esophageal varicies and splenomegaly.
Prior to transplant, BB was EBV sero-negative
and CMV sero-negative. BB underwent ortho-
topic liver transplantation 3 months after evalu-
ation with placement of an endobiliary stent.
The donor was a CMV sero-negative, EBV














sero-positive 3 yr old. BB was started on tacrol-
imus, MMF, and prednisone. His post-operative
course was uneventful and BB was discharged on
post-operative day number five receiving viral
prophylaxis with acyclovir. BB received a single
dose pulse of steroids for a presumed rejection as
a result of rising liver function tests, which was
not confirmed by graft biopsy.
The patient was re-admitted 6 wk after trans-
plantation with fever to 102.5 following removal
of his endobilliary stent. The blood, urine and
sputum cultures were obtained, but no patho-
logic organisms were isolated by laboratory
culture. His liver function tests were unremark-
able and BB was clinically asymptomatic. BB
was subsequently discharged with low-grade
fevers. EBV–PCR demonstrated 8 copies per
105 lymphocytes (Table 2). Following his dis-
charge, the patient complained of recurrent
low-grade fevers and abdominal pain. Physical
examination revealed tonsillar enlargement.
Given these findings, a repeat EBV–PCR was
obtained and there was a transient rise in his
titers from 8 to 100 copies. An abdominal-pelvic
CT was obtained which demonstrated a small
hypodense lesion in the left lobe of the liver and
multiple small areas in the parenchyma of the
right kidney showing no enhancement that were
suspicious but not diagnostic for PTLD. The
immunosuppression was not altered given the
results of the EBV–PCR. Both the CT scan and
the EBV–PCR were subsequently repeated with-
in 1 month. These repeat studies demonstrated a
reduction in viral load to 40 genomes per 105
lymphocytes and no visible lesions on CT.
BB did well for an additional 2 months when
BB developed nausea, vomiting and weight loss.
BB was evaluated with EGD and colonoscopy
that were normal. BB was also noted to have
persistent tonsillar enlargement, and underwent
tonsillectomy. Pathologic examination revealed
no PTLD. Three weeks following tonsillectomy,
BB represented with decreased oral intake,
weight loss, and repeat CT scan demonstrated
irregular thickening of several small intestinal
loops in the right lower quadrant consistent with
PTLD. Repeat EBV–PCR revealed only 80
genomes per 105 lymphocytes. The patient was
then taken for exploratory laparoscopy 1 wk
later, which was converted, to open laparotomy.
At operation, a large right lower quadrant mass
involving 12 cm of distal ilium was resected. BB
was also found to have massive mesenteric
adenopathy. Pathologic examination of this mass
demonstrated a diffuse large B-cell lymphoma
(monomorphic PTLD). Numerous cells were
positive for EBV–LMP as well as CD20. PET
scanning obtained post-operatively demonstra-
ting 11 foci of abnormally increased FDG uptake
in the mid abdomen, corresponding to lymph
nodes involved with his neoplasm.
Following his diagnosis, the patient’s immu-
nosuppression was withdrawn and was treated
with four doses of Rituximab. Six weeks
following diagnosis and withdrawal of his
immunosuppression, BB had rising liver func-
tion tests. BB was biopsied and treated for acute
cellular rejection. Despite initial improvement
with pulse steroids, the patient’s liver function
has continued to worsen. Subsequent biopsy has
demonstrated chronic rejection, and BB is now
being considered for retransplantation. Follow-
ing completion of therapy with Rituximab and
six cycles of cytoxan, the patient’s CT scan
demonstrated complete regression of his tumor.
Repeat PET scan demonstrated no active dis-
ease.
Discussion
The development of PTLD represents one of the
most lethal complications of solid organ trans-
plantation. The incidence of PTLD varies
by organ and has been reported in 2.6–9.0%
of pediatric renal transplant recipients (8–11)
with malignancy developing in 1.5%. Among
liver recipients, PTLD has been diagnosed in
6.8–13.1% of recipients (12, 13). Furthermore,
the incidence of PTLD appears to be increasing
in pediatric renal transplant recipients from 298
to 395 cases per 100 000 yr of patient follow-up
(13).
Detection of PTLD requires a high index of
suspicion, particularly among patients with
known risk factors including: younger age at
transplant, EBV negative recipients transplanted
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with an EBV positive organ, CMV infection,
OKT3 treatment, and, possibly, tacrolimus based
immunosuppression. In patients suspected of
having PTLD, an aggressive diagnostic evalua-
tion with radiographic imagining and serologic
evaluation is indicated as early diagnosis may be
correlated with better outcome (14). Histologic
evaluation of an appropriate biopsy specimen is
necessary to differentiate PTLD from acute
cellular rejection, which often has a similar
presentation.
Given the difficulty in identifying PTLD, viral
load monitoring has been a very useful addition
to the diagnostic techniques. Elevated levels of
EBV DNA have been correlated with PTLD in
several non-quantitative assays. The presence of
low levels of EBV viral DNA is not uncommon
in the immunosuppressed population, and has
been documented in up to 19% of healthy solid
organ transplant recipients (6). The development
of a quantitative PCR technique has significantly
improved the specificity for PTLD and may serve
as an early marker in high-risk patients. Quan-
titative PCR as originally described by Rowe and
colleagues utilized a competitive PCR assay in
which viral load was quantified by co-amplifying
varying quantities of a competitor plasmid under
identical conditions (3). Using this assay, 13 of 14
patients with PTLD had >500 copies per 105
lymphocytes. The resulting sensitivity was repor-
ted as 92.8% and the specificity was 100% (3).
PCR has also been effectively used to monitor
high risk transplant patients and identify those
with an increase risk for PTLD (15). Frequent
monitoring and treatment with reduction of
immunosuppression and anti-viral therapy has
been reported to reduce the incidence of PTLD in
pediatric liver transplant patients from 10 to 5%
when compared with historical controls (16).
Similarly in children undergoing small bowel
transplant, the use of frequent monitoring has
resulted in a reduction in the incidence of PTLD
from 40 to 11% (17). EBV–PCR monitoring has
also proven to be a useful strategy following the
treatment of PTLD. Response to therapy is
correlated with a decrease in viral load to <200
copies per 105 cells (18). This reduction is
reflective of an effective immune response against
EBV-infected B-cells and is an early predictor
of clinical outcome (15). Persistence of viral
loads less than this level appears to signal that
re-introduction of low dose immunosuppression
is safe.
While EBV–PCR clearly has a role in the
clinical management of the post-transplant
patient, several limitations have been recog-
nized. First, as shown by the patients included
in this report, quantitative EBV–PCR may fail
to identify patients with PTLD whose viral
loads fail to meet an identified threshold value.
Green and colleagues described a similar child
in whom PTLD with nervous system involve-
ment was diagnosed in a patient who had a past
history of systemic PTLD. This child was noted
to have a low EBV load by PCR despite active
disease. Second, there may be an overlap in
viral levels in patients with PTLD and EBV-
associated viral syndromes (19). Finally, the
significance of viral levels in the post-PTLD
patient remains unclear. Patients may have a
rebound in their viral load following the
re-introduction of immunosuppression. How-
ever, the vast majority will not develop recur-
rent disease (15).
It is not clear why EBV–PCR monitoring
failed to identify the development of PTLD in
our patients. In patient AA, the late development
(91 months post-transplant) of Hodgkin’s dis-
ease, an uncommon histologic subtype may be
responsible. While late onset PTLD has been
associated with a higher incidence of EBV
negative tumors, this was not the case in this
patient as her tumor was proven to be EBV
positive (2). The second patient had recently
received acyclovir, which may have artificially
suppressed his viral load. However, the bulk of
the viral load in peripheral blood in patients with
PTLD is believed to be related to immortalized
cells and not lytic infection [which is suppressed
by anti-viral agents (19)] Furthermore, EBV viral
loads may climb, even in the face of i.v. acyclovir
or gancilovir (16). Thus, it appears unlikely that
the acyclovir therapy is primarily responsible for
the low levels of EBV documented in this case.
Hopefully, the availability of rapid, accurate
viral load monitoring will facilitate further
research to understand the pathologic basis of
PTLD in patients who do not manifest high viral
loads.
In summary, we report two cases of PTLD
in patients with very low viral loads. Each
patient was high risk for PTLD based on his or
her initial EBV serology. While our clinical
suspicion remained high, the resulting low
EBV–PCR may have provided a false sense of
re-assurance. In both instances, the use of CT
technology was diagnostic once lesions of
sufficient size had developed. While EBV–PCR
remains a useful screening test in patients who
are at high risk for PTLD, a significant
minority of patients may have active disease
despite low viral loads and alternative diagnos-
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